- Home
- KZIA vs WINT Comparison
KZIA vs WINT Comparison
Compare KZIA & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- WINT
- Stock Information
- Founded
- KZIA 1994
- WINT 1992
- Country
- KZIA Australia
- WINT United States
- Employees
- KZIA N/A
- WINT N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KZIA Health Care
- WINT Health Care
- Exchange
- KZIA Nasdaq
- WINT Nasdaq
- Market Cap
- KZIA 860.8K
- WINT 996.6K
- IPO Year
- KZIA 1999
- WINT 1995
- Fundamental
- Price
- KZIA $3.64
- WINT $1.21
- Analyst Decision
- KZIA Strong Buy
- WINT Hold
- Analyst Count
- KZIA 2
- WINT 1
- Target Price
- KZIA $57.50
- WINT $350.00
- AVG Volume (30 Days)
- KZIA 30.1K
- WINT 347.1K
- Earning Date
- KZIA 05-02-2025
- WINT 05-06-2025
- Dividend Yield
- KZIA N/A
- WINT N/A
- EPS Growth
- KZIA N/A
- WINT N/A
- EPS
- KZIA N/A
- WINT N/A
- Revenue
- KZIA $1,655,324.00
- WINT N/A
- Revenue This Year
- KZIA N/A
- WINT N/A
- Revenue Next Year
- KZIA N/A
- WINT N/A
- P/E Ratio
- KZIA N/A
- WINT N/A
- Revenue Growth
- KZIA 248000.00
- WINT N/A
- 52 Week Low
- KZIA $2.86
- WINT $1.01
- 52 Week High
- KZIA $79.00
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- KZIA 44.45
- WINT 35.07
- Support Level
- KZIA $2.86
- WINT $1.01
- Resistance Level
- KZIA $3.77
- WINT $1.19
- Average True Range (ATR)
- KZIA 0.50
- WINT 0.14
- MACD
- KZIA 0.05
- WINT 0.12
- Stochastic Oscillator
- KZIA 60.00
- WINT 41.67
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.